4 completed, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow CORT118335: new trials by email Literature Review of CORT118335 trials Research Report on CORT118335
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B) - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Completed | Corcept Therapeutics | 175 | 2023-10-25 | 2026-09-29 |
| Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo Miricorilant, Placebo oral tablet - Alcohol Use Disorder | Phase 2 | Completed | The Scripps Research Institute | 50 | 2021-04-15 | 2023-02-03 |
| Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) Miricorilant, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Terminated | Corcept Therapeutics | 12 | 2020-11-04 | 2022-08-31 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) Miricorlilant, Placebo - Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | Completed | Corcept Therapeutics | 150 | 2020-09-09 | 2024-06-13 |
| A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications Miricorilant, Placebo - Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | Completed | Corcept Therapeutics | 71 | 2019-12-04 | 2024-09-19 |
Mental Disorders (2) · Non-alcoholic Fatty Liver Disease (2) · Obesity (2) · Schizophrenia (2) · Weight Gain (2) · Alcohol-Related Disorders (1) · Alcoholism (1) · Bipolar Disorder (1)
Corcept Therapeutics (4) · The Scripps Research Institute (1)
United States (5) · India (1) · Puerto Rico (1)
Kavita Juneja, MD (3) · Barbara J. Mason, Ph.D. (1)
U01AA025476 (1)